FDA Issues Patent Extension Review Determination for SUNLENCA
May 10, 2025
May 10, 2025
WASHINGTON, May 10 (TNSFR) -- The U.S. Department of Health and Human Services Food and Drug Administration has issued a formal notice identifying the regulatory review period for the human drug product SUNLENCA, initiating a key step in the process that may lead to an extension of its patent.
SUNLENCA, developed by pharmaceutical company Gilead Sciences, Inc., is an antiretroviral treatment used in the management of HIV-1 infection. The Food and Drug Administration made this deter . . .
SUNLENCA, developed by pharmaceutical company Gilead Sciences, Inc., is an antiretroviral treatment used in the management of HIV-1 infection. The Food and Drug Administration made this deter . . .